Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7577960 | 0.82 | ACKR3 (0.47) | HDAC6MAPTKCNH2HRH3ACKR3 | |
| SCHEMBL5935574 | 0.80 | KCNH2 (0.53) | MAPTKCNH2HRH3ACKR3RXFP1 | |
| SCHEMBL6555820 | 0.79 | KCNH2 (0.46) | HDAC6MAPTKCNH2HRH3ACKR3 | |
| SCHEMBL6556054 | 0.79 | PPARG (0.55) | MAPTKCNH2HRH3ACKR3 | |
| SCHEMBL6555767 | 0.79 | PPARG (0.68) | — | |
| Lithium Ion SCHEMBL7004812 | 0.78 | PPARG (0.59) | MAPT | |
| SCHEMBL7006236 | 0.78 | PPARG (0.59) | MAPT | |
| SCHEMBL5935611 | 0.78 | KCNH2 (0.52) | MAPTKCNH2HRH3RXFP1MEN1 | |
| Lithium SCHEMBL7004819 | 0.78 | PPARG (0.67) | — | |
| SCHEMBL7006234 | 0.78 | PPARG (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | CYP3A43, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | HDAC6 76/4885MAPT 35/4885KCNH2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.